Loading stock data…
ORMP
$3.98+0.10 (+2.58%)
Market ClosedLast close May 1
Oramed Pharmaceuticals Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Oramed Pharmaceuticals Inc. in the Healthcare sector is trading at $3.98. The stock is currently near its 52-week high of $4.22, remaining 44.2% above its 200-day moving average. Technical signals show neutral RSI of 60 and bullish MACD crossover, explaining why ORMP maintains its current momentum and trend strength. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Neutral momentum (RSI 60) — price action in range
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$3.98
Potential Upside
853.6%
Whystock Fair Value$37.95
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical t...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$155.31M
P/E Ratio
Value territory. Trading at a high yield relative to earnings.
2.56
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.25
Div Yield
Strong income play. Yield provides a meaningful total return floor.
639.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
32.07%
Volume
Today's trading volume
107,946
Recent News
Oramed Pharmaceuticals And Two Other Promising Penny Stocks For Savvy Investors
The market has shown impressive growth, with a 4.2% increase over the last week and a 29% rise over the past year, while earnings are projected to grow by 16% annually. Although the term 'penny stock' may seem outdated, it still represents an area of investment that can uncover significant opportunities in smaller or newer companies. By focusing on those with strong financials and clear growth potential, investors can find hidden value in quality penny stocks that offer both stability and...
Oramed: Q4 Earnings Snapshot
NEW YORK (AP) — Oramed Pharmaceuticals Inc. ORMP) on Thursday reported profit of $10 million in its fourth quarter. The New York-based company said it had net income of 24 cents per share.
CarMax Stock Down 47% This Past Year, But One Fund Is Betting $6 Million on a Turnaround
CarMax runs a nationwide network of used car stores and digital channels, offering multi-channel sales and financing to U.S. consumers.
Alumis Stock Has Rallied 250% This Past Year. One Fund Sold Its $5 Million Stake Last Quarter.
This clinical-stage biotech develops therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition.
3 Promising Penny Stocks With Market Caps Under $200M
As the S&P 500 and Dow Jones Industrial Average reach new highs, investors continue to navigate a landscape marked by both opportunities and challenges. For those looking to invest in smaller or newer companies, penny stocks — despite the name's vintage feel — can still offer surprising value. With solid financial foundations, these stocks have the potential to outperform while offering greater stability.